BIOMAT Database Logo BIOMAT Database Logo

Antibiotic resistance in community-acquired respiratory tract infections: current issues. 1998

D H Spach, and D Black
Division of Infectious Diseases, University of Washington, Seattle, USA.

OBJECTIVE In recent years, antibiotic resistance has emerged as an important global problem. The major goal of this review is to update important issues pertaining to antibiotic resistance, with an emphasis on antibiotic resistance involving community-acquired respiratory pathogens. In addition, this review examines potential reasons why antibiotic resistance has increased in recent years, how clinicians can better understand commonly used laboratory antibiotic resistance tests, and possible solutions to the increasing problem of antibiotic resistance. The article emphasizes the diagnosis, therapy, and prevention of antibiotic-resistant infections. METHODS We identified relevant English-language articles through MEDLINE search (1966 to March 1998). All articles related to antibiotic resistance and the scope of the articles included original investigative articles, reviews, letters, and editorials. In addition, we selected additional references from the bibliographies of the identified articles. METHODS We selected articles for detailed review if they provided direct insight into the cause of antibiotic resistance, testing for antibiotic resistance, or the treatment of antibiotic resistance. Most, but not all, of the articles selected pertained to antibiotic resistance and respiratory tract infections. We performed a detailed review on approximately 40% of the originally selected articles. RESULTS Multiple factors that play a significant role in the development of antibiotic resistance include the overuse of antibiotics in both humans and animals, situations such as day care that enhance transmission via frequent close personal contact, and widespread dissemination of resistant strains via global travel. Most respiratory pathogens have developed resistance to commonly used antibiotics either by producing beta-lactamase or by altering binding site proteins. CONCLUSIONS In many regions of the United States, the level of antibiotic resistance has impacted the clinical management of common respiratory pathogens. Future efforts to curtail antibiotic resistance will require a concerted effort in multiple areas, particularly enhanced epidemiologic surveillance to better detect resistance trends, judicious use of antibiotics, and new drug development.

UI MeSH Term Description Entries
D008826 Microbial Sensitivity Tests Any tests that demonstrate the relative efficacy of different chemotherapeutic agents against specific microorganisms (i.e., bacteria, fungi, viruses). Bacterial Sensitivity Tests,Drug Sensitivity Assay, Microbial,Minimum Inhibitory Concentration,Antibacterial Susceptibility Breakpoint Determination,Antibiogram,Antimicrobial Susceptibility Breakpoint Determination,Bacterial Sensitivity Test,Breakpoint Determination, Antibacterial Susceptibility,Breakpoint Determination, Antimicrobial Susceptibility,Fungal Drug Sensitivity Tests,Fungus Drug Sensitivity Tests,Sensitivity Test, Bacterial,Sensitivity Tests, Bacterial,Test, Bacterial Sensitivity,Tests, Bacterial Sensitivity,Viral Drug Sensitivity Tests,Virus Drug Sensitivity Tests,Antibiograms,Concentration, Minimum Inhibitory,Concentrations, Minimum Inhibitory,Inhibitory Concentration, Minimum,Inhibitory Concentrations, Minimum,Microbial Sensitivity Test,Minimum Inhibitory Concentrations,Sensitivity Test, Microbial,Sensitivity Tests, Microbial,Test, Microbial Sensitivity,Tests, Microbial Sensitivity
D012141 Respiratory Tract Infections Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases. Respiratory System Infections,Upper Respiratory Tract Infection,Upper Respiratory Tract Infections,Infections, Respiratory,Infections, Respiratory Tract,Infections, Upper Respiratory,Infections, Upper Respiratory Tract,Respiratory Infections,Upper Respiratory Infections,Infection, Respiratory System,Infection, Respiratory Tract,Respiratory Infection, Upper,Respiratory System Infection,Respiratory Tract Infection
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D017714 Community-Acquired Infections Any infection acquired in the community, that is, contrasted with those acquired in a health care facility (CROSS INFECTION). An infection would be classified as community-acquired if the patient had not recently been in a health care facility or been in contact with someone who had been recently in a health care facility. Community Acquired Infection,Community-Acquired Infection,Infections, Community-Acquired,Acquired Infection, Community,Acquired Infections, Community,Community Acquired Infections,Infection, Community Acquired,Infection, Community-Acquired,Infections, Community Acquired

Related Publications

D H Spach, and D Black
Resistance issues and community-acquired respiratory infections.
January 2003, Clinical cornerstone,
D H Spach, and D Black
Antibiotic resistance in community-acquired urinary tract infections.
September 1994, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
D H Spach, and D Black
Appropriate antibiotic therapy for community-acquired respiratory tract infections.
December 2005, Managed care interface,
D H Spach, and D Black
Treatment with appropriate antibiotic therapy in community-acquired respiratory tract infections.
October 2004, The American journal of managed care,
D H Spach, and D Black
Antibiotic kinetic and dynamic attributes for community-acquired respiratory tract infections.
December 2000, The American journal of managed care,
D H Spach, and D Black
[Macrolide antibiotic clarithromycin (Klabax) in treatment of community-acquired respiratory tract infections].
January 2000, Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic],
D H Spach, and D Black
Clinical implications of macrolide resistance in community-acquired respiratory tract infections.
December 2006, Expert review of anti-infective therapy,
D H Spach, and D Black
Surveillance of resistance in bacteria causing community-acquired respiratory tract infections.
January 2002, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,
D H Spach, and D Black
Community-acquired bacterial respiratory tract infections.
March 2005, The Journal of family practice,
D H Spach, and D Black
[Antibiotic resistance and community-acquired infections].
March 2002, Recenti progressi in medicina,
Copied contents to your clipboard!